• 1
    Neri, M, Spanevello, A. Chronic bronchial asthma from challenge to treatment: epidemiology and social impact. Thorax 2000; 55;Suppl 2: S578.
  • 2
    Sears, MR. Descriptive epidemiology of asthma. Lancet 1997; 350;Suppl 2: S14.
  • 3
    Sly, RM. Changing prevalence of allergic rhinitis and asthma. Ann Allergy Asthma Immunol 1999; 82: 23348.
  • 4
    Valdivia, G. Asma bronquial y enfermedades atopicas como problema emergente de Salud Publica: nuevas hipotesis etiologicas. La experiencia de sociedades desarrolladas. Rev Med Chil 2000; 128: 33946.
  • 5
    Grant, EN, Wagner, R, Weiss, KB. Observations on emerging patterns of asthma in our society. J Allergy Clin Immunol 1999; 104:(2 Pt 2):S19.
  • 6
    Hartert, TV, Peebles, RSJr. Epidemiology of asthma: the year in review. Curr Opin Pulm Med 2000; 6: 49.
  • 7
    Leuenberger, P. Pollution de l’air en Suisse et maladies respiratoires chez l’adulte. Resultats preliminaires de la partie transversale de l’etude Sapaldia. Schweiz Rundsch Med Prax 1995; 84: 1096100.
  • 8
    Weiss, KB, Sullivan, SD. The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol 2001; 107: 38.
  • 9
    Szucs, TD, Anderhub, HP, Rutishauser, M. Determinants of health care costs and patterns of care of asthmatic patients in Switzerland. Schweiz Med Wochenschr 2000; 130: 30513.
  • 10
    Szucs, TD, Anderhub, H, Rutishauser, M. The economic burden of asthma: direct and indirect costs in Switzerland. Eur Respir J 1999; 13: 2816.
  • 11
    Konkordat der Schweizerischen Krankenversicherer. Tagestaxen in HeilanstaltenBern: Korkordat der Schweizerischen Krankenversicherer; 1999.
  • 12
    Anonymous. Arzneimittelkompendium der Sch-weizBasel: Documed; 1997.
  • 13
    Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention (updated from NHLBI/WHO Workshop Report: Global Strategy for Asthma Management and Prevention, issued January 1995): NIH Publication No. 02-3659. Bethesda: National Institutes of Health. National Heart, Lung, and Blood Institute; 2002.
  • 14
    Cockcroft, DW, Swystun, VA. Asthma control versus asthma severity. J Allergy Clin Immunol 1996; 98:(6 Pt 1):10168.
  • 15
    Altman, DG. Practical Statistics for Medical Research. 1st ed. London: Chapman & Hall/CRC; 1991.
  • 16
    Barnes, PJ, Jonsson, B, Klim, JB. The costs of asthma. Eur Respir J 1996; 9: 63642.
  • 17
    Graf von der Schulenburg, JM, Greiner, W, Molitor, S, Kielhorn, A. Kosten der Asthmatherapie nach Schweregrad. Eine empirische Untersuchung. Med Klin 1996; 91: 6706.
  • 18
    Serra-Batlles, J, Plaza, V, Morejon, E, et al. Costs of asthma according to the degree of severity. Eur Respir J 1998; 12: 13226.
  • 19
    Ungar, WJ, Coyte, PC, Chapman, KR, MacKeigan, L. The patient level cost of asthma in adults in south central Ontario. Pharmacy Medication Monitoring Program Advisory Board. Can Respir J 1998; 5: 46371.
  • 20
    Malone, DC, Lawson, KA, Smith, DH. Asthma: an analysis of high cost patients. Pharm Pract Manage Q 2000; 20: 1220.
  • 21
    Hoskins, G, McCowan, C, Neville, RG, et al. Risk factors and costs associated with an asthma attack. Thorax 2000; 55: 1924.
  • 22
    Plaza, V, Serra-Batlles, J, Ferrer, M, Morejon, E. Quality of life and economic features in elderly asthmatics. Respiration 2000; 67: 6570.
  • 23
    Morgan, RO, Virnig, BA, DeVito, CA, Persily, NA. The Medicare–HMO revolving door—the healthy go in and the sick go out. N Engl J Med 1997; 337: 16975.
  • 24
    Age- and state-specific prevalence estimates of insured and uninsured persons in the United States 1995–96. MMWR v; 47: 52932.
  • 25
    Rutten van Molken, MP, Postma, MJ, et al. Current and future medical costs of asthma and chronic obstructive pulmonary disease in The Netherlands. Respir Med 1999; 93: 77987.